Adicet Bio, Inc. (ACET) — SEC Filings
Adicet Bio, Inc. (ACET) — 50 SEC filings. Latest: 4 (Apr 29, 2026). Includes 24 8-K, 8 SC 13G/A, 6 10-Q.
View Adicet Bio, Inc. on SEC EDGAR
Overview
Adicet Bio, Inc. (ACET) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Mar 24, 2026: The SEC has declared Adicet Bio, Inc.'s registration statement (File No. 333-294265) effective as of March 23, 2026. This means the company can now proceed with the offering of securities described in that registration statement. For investors, this is a procedural step that clears the way for Adice
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 4 bearish, 46 neutral. The dominant filing sentiment for Adicet Bio, Inc. is neutral.
Filing Type Overview
Adicet Bio, Inc. (ACET) has filed 1 4, 3 144, 1 EFFECT, 24 8-K, 3 DEF 14A, 6 10-Q, 2 10-K, 8 SC 13G/A, 1 SC 13D/A, 1 SC 13G with the SEC between Feb 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of ACET's 36 recent filings, 4 were flagged as high-risk, 12 as medium-risk, and 20 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$26.856M |
| EPS | N/A |
| Debt-to-Equity | 0.29 |
| Cash Position | $29.099M |
| Operating Margin | N/A |
| Total Assets | $140.479M |
| Total Debt | $31.337M |
Key Executives
- Chen Schor
- Nick Harvey
- Dr. Steven T. Rosen
- Dr. Steven J. Altschuler
- Ms. Laura J. Brege
- ChenSchor
- Carl L. Gordon
- Erez Chimovits
Industry Context
The biotechnology industry, particularly the clinical-stage segment, is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies like Adicet Bio rely heavily on successful clinical trials and subsequent funding rounds to advance their drug candidates. The competitive landscape is intense, with numerous companies vying for market share and investor capital.
Top Tags
sec-filing (8) · financials (5) · 8-k (5) · corporate-governance (4) · Biotechnology (4) · 10-Q (4) · corporate-action (3) · pharmaceuticals (3) · executive-compensation (3) · 8-K (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Closing bid price per share | $0.66 | On November 14, 2025, below Nasdaq's $1.00 requirement |
| Nasdaq minimum bid price requirement | $1.00 | Threshold for continued listing on Nasdaq Capital Market |
| Shares of common stock outstanding | 153,255,581 | As of November 14, 2025, entitled to vote |
| Calendar days | 180 | Initial compliance period provided by Nasdaq |
| Shares for quorum | 76,627,791 | Majority of outstanding shares required for Special Meeting quorum |
| Minimum reverse stock split ratio | 1-for-5 | Board's discretion range for the split |
| Maximum reverse stock split ratio | 1-for-30 | Board's discretion range for the split |
| Record Date | 2025-11-14 | Date for determining stockholders entitled to vote |
| Special Meeting Date | 2025-12-19 | Date stockholders will vote on the reverse stock split |
| Nasdaq Notice Date | 2025-04-07 | Date Adicet Bio received non-compliance notice |
| Net Loss (Q3 2025) | $26.856M | Improved from $30.478M in Q3 2024, but still a significant loss. |
| Net Loss (9 Months 2025) | $86.287M | Slightly better than $88.395M in 9 months 2024, indicating continued burn. |
| Cash & Cash Equivalents | $29.099M | As of Sep 30, 2025, down 48.5% from $56.495M at Dec 31, 2024. |
| Short-term Investments | $73.999M | As of Sep 30, 2025, down 38.3% from $119.808M at Dec 31, 2024. |
| R&D Expenses (Q3 2025) | $22.853M | Decreased from $26.253M in Q3 2024, reflecting pipeline prioritization. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Adicet Bio, Inc. (ACET)?
Adicet Bio, Inc. has 50 recent SEC filings from Feb 2024 to Apr 2026, including 24 8-K, 8 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ACET filings?
Across 50 filings, the sentiment breakdown is: 4 bearish, 46 neutral. The dominant sentiment is neutral.
Where can I find Adicet Bio, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Adicet Bio, Inc. (ACET) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Adicet Bio, Inc.?
Key financial highlights from Adicet Bio, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ACET?
The investment thesis for ACET includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Adicet Bio, Inc.?
Key executives identified across Adicet Bio, Inc.'s filings include Chen Schor, Nick Harvey, Dr. Steven T. Rosen, Dr. Steven J. Altschuler, Ms. Laura J. Brege and 3 others.
What are the main risk factors for Adicet Bio, Inc. stock?
Of ACET's 36 assessed filings, 4 were flagged high-risk, 12 medium-risk, and 20 low-risk.
What are recent predictions and forward guidance from Adicet Bio, Inc.?
Forward guidance and predictions for Adicet Bio, Inc. are extracted from SEC filings as they are enriched.